

NCT ID	NCT05438342
Title	An Expanded Clinical Study of Triple Therapy for Refractory Solid Tumors That Failed First-line Treatment for Recurrence and Metastasis
Phase	Not Applicable
Date Added	2022-06-29
Location	China
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	Chemotherapy?checkpoint immunotherapy, targeted therapy
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05611034
Title	In Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung
Phase	Phase 1
Date Added	2022-11-09
Location	Canada
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	oxaliplatin
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05479812
Title	Dose Escalation Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
Phase	Phase 1
Date Added	2022-07-29
Location	Arizona, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Minnesota, United States New Jersey, United States New York, United States Oregon, United States Texas, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	Pembrolizumab, WTX-124
Tags	MSI-H/ MMRd
NCT ID	NCT05487235
Title	A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Phase	Phase 1
Date Added	2022-08-04
Location	Argentina Australia Brazil Canada Korea, Republic of New Zealand

Prior IO Allowed	Yes
CRC-directed	No
Status	Completed
Drugs	Atezolizumab, GDC-1971, Omeprazole
Tags	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
NCT ID	NCT05491317
Title	A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors
Phase	Phase 1, Phase 2
Date Added	2022-08-08
Location	France
Prior IO Allowed	Yes
CRC-directed	No
Status	Terminated
Drugs	Pembrolizumab
Tags	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
NCT ID	NCT05493683
Title	Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer
Phase	Phase 2
Date Added	2022-08-09
Location	China,China,China,China,China,China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Disitamab vedotin, Tislelizumab
Tags	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
NCT ID	NCT05328908
Title	A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer
Phase	Phase 3
Date Added	2022-04-14

Location	Arkansas, United States
	California, United States
	Connecticut, United States
	Florida, United States
	Georgia, United States
	Idaho, United States
	Indiana, United States
	Massachusetts, United States
	Michigan, United States
	New Jersey, United States
	North Carolina, United States
	Ohio, United States
	Pennsylvania, United States
	South Carolina, United States
	South Dakota, United States
	Tennessee, United States
	Texas, United States
	Virginia, United States
	Wisconsin, United States
	Argentina
	Australia
	Austria
	Belgium
	Canada
	Chile
	China
	Czechia
	France
	Germany
	Italy
	Japan
	Korea, Republic of
	Netherlands
	Poland
	Puerto Rico
	Singapore
	Spain
	Sweden
	Switzerland
	Taiwan
Prior IO Allowed	No
CRC-directed	Yes
Status	Terminated
Drugs	Nivolumab-relatlimab FDC, Regorafenib, TAS-102, Lonsurf, Opdivo, Stivarga
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT05673148
Title	Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
Phase	Phase 3
Date Added	2023-01-06

Location	Arizona, United States
	California, United States
	Delaware, United States
	District of Columbia, United States
	Florida, United States
	Georgia, United States
	Idaho, United States
	Illinois, United States
	Iowa, United States
	Kentucky, United States
	Louisiana, United States
	Maryland, United States
	Massachusetts, United States
	Michigan, United States
	Minnesota, United States
	Mississippi, United States
	Missouri, United States
	Montana, United States
	Nebraska, United States
	Nevada, United States
	New Hampshire, United States
	New Jersey, United States
	New Mexico, United States
	New York, United States
	North Carolina, United States
	North Dakota, United States
	Ohio, United States
	Oklahoma, United States
	Oregon, United States
	Pennsylvania, United States
	South Dakota, United States
	Tennessee, United States
	Texas, United States
	Utah, United States
	Virginia, United States
	Washington, United States
	West Virginia, United States
	Wisconsin, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Chemotherapy
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT05425940
Title	Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303)
Phase	Phase 3
Date Added	2022-06-21

Location	Alabama, United States Arizona, United States California, United States Connecticut, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Kansas, United States Kentucky, United States Louisiana, United States Missouri, United States Montana, United States Nebraska, United States New Mexico, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Virginia, United States Washington, United States Australia Belgium France Germany Hong Kong Hungary New Zealand Poland Portugal Singapore South Korea Spain Taiwan Thailand United Kingdom
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Regorafenib, XL092, Stivarga, Tecentriq
Tags	MSS/ MMRp
NCT ID	NCT05627635
Title	FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer
Phase	Phase 1, Phase 2
Date Added	2022-11-25
Location	California, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Balstilimab, Botensilimab, fluorouracil, Leucovorin Calcium, oxaliplatin
Tags	MSS/ MMRp